Loss of PTEN expression leading to high Akt activation in human multiple myelomas

Blood

Volumn 96, Issue 10, 2000, Pages 3560-3568

  Hyun, T ^a   Yam, A ^a   Pece, S ^a   Xie, X ^a   Zhang, J ^a   Miki, T ^a   Gutkind, J S ^a   Li, W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL KINASE; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; ENZYME ACTIVITY; EXON; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 0034669945     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.10.3560.h8003560_3560_3568     Document Type: Article

References (53)

1. Biology and treatment of multiple myeloma
2. Multiple myeloma: Increasing evidence for a multistep transformation process
3. Myeloma biology and therapy: Present status and future developments
4. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
5. Cytogenetics and molecular genetics in multiple myeloma
6. Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations
7. Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants
8. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice
9. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane)
10. Susceptibility and resistance to J3V1 retrovirus-induced murine plasmacytomagenesis in reconstituted severe combined immunodeficient mice
11. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice
12. An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis
13. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas
14. Interleukin 6 is essential for in vivo development of B lineage neoplasms
15. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors
16. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway
17. Experimental plasmacytomagenesis in mice
18. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth
19. The role of phosphoinositide 3-kinase lipid products in cell function
20. Phosphoinositide kinases
21. PI3K: Downstream AKTion blocks apoptosis
22. The PI3K-PDK1 connection: More than just a road to PKB
23. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
24. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that Is mutated in multiple advanced cancers
25. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
26. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
27. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
28. The multiple roles of PTEN in tumor suppression
29. The lipid phosphatase activity of PTEN is critical for its tumor supressor function
30. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
31. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC
32. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
33. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
34. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
35. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
36. Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation
37. The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R gamma chain is involved in interleukin-13-mediated signal transduction
38. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression
39. Protein kinase C-α overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal
40. Mechanism of activation of protein kinase B by insulin and IGF-I
41. The 70 kDa S6 kinase: Regulation of a kinase with multiple roles in mitogenic signalling
42. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha
43. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase
44. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase
45. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region
46. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily
47. Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k
48. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation
49. Mutational analysis of the PTEN/MMAC1 gene in nonHodgkin's lymphoma
50. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies
51. PTEN gene alterations in lymphoid neoplasms
52. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway